The first clinical trial using a non-selective NOS inhibitor L-NGmethylarginine hydrochloride (L-NMMA, 546 C88) to assess its efficacy in acute migraine treatment [144] showed the headache response at 2 h was 67% in the treatment arm compared with 14% in the placebo arm. The gene discussed is NOS2; the disease is migraine disorder.